<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656485</url>
  </required_header>
  <id_info>
    <org_study_id>AVB244-001</org_study_id>
    <nct_id>NCT02656485</nct_id>
  </id_info>
  <brief_title>A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOBiome LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AOBiome LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blind, placebo-controlled study in subjects with
      acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a screening visit and a one-week washout (if applicable), three sequential ascending
      doses of the study drug will be applied twice-daily (BID) for 14 days in three groups of
      subjects. Each group of subjects will be randomized to receive the planned doses of B244 or
      placebo BID
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2015</start_date>
  <completion_date type="Actual">July 15, 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Number of Participants With Treatment Related Adverse Events)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Absolute Change from Baseline in Total Number of Lesions</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Dose I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B244 Dose 1 (dose level [cells/mL] 20,000,000,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B244 Dose 2 (dose level [cells/mL] 40,000,000,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B244 Dose 3 (dose level [cells/mL] 80,000,000,000)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Match B244</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B244</intervention_name>
    <description>10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
    <arm_group_label>Dose I</arm_group_label>
    <arm_group_label>Dose II</arm_group_label>
    <arm_group_label>Dose III</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
    <arm_group_label>Dose I</arm_group_label>
    <arm_group_label>Dose II</arm_group_label>
    <arm_group_label>Dose III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects ≥18 and ≤45 years of age

          2. In good general health as determined by a thorough medical history and physical
             examination, electrocardiogram (ECG), vital signs, and clinical laboratory evaluation.
             Results of clinical laboratory tests must be without clinically significant
             abnormalities, including hematology, clinical chemistry and urinalysis.

          3. Clinical diagnosis of facial acne vulgaris defined as:

               -  ≥105 inflammatory lesions

               -  ≥10 non-inflammatory lesions

               -  IGA ≥2

          4. Willing to refrain from using any treatments, other than the investigational product,
             including antibiotics, for acne present on the face. Topical acne treatments that do
             not have significant or measurable systemic absorption (e.g., benzoyl peroxide,
             salicylic acid) are allowed for treatment of acne of the back, shoulders and chest
             only.

          5. Ability to comprehend and comply with procedures

          6. Agree to commit to participate in the current protocol

          7. Provide written informed consent prior to any study procedure being performed (all
             subjects should be able to understand the informed consent form and any other
             documents that subjects are required to read)

        Exclusion Criteria:

          1. Female subjects who are pregnant or lactating or who are trying to conceive

          2. Female subjects with a positive urine β-human chorionic gonadotropin (β-hCG) test at
             screening or positive β-hCG urine at pre-dose

          3. Any clinically relevant abnormality identified on the screening history, physical or
             laboratory examinations, or any other medical condition or circumstance making the
             volunteer unsuitable for participation in the study

          4. Any skin condition which may interfere with the evaluation of safety or of acne
             vulgaris (e.g., rosacea; seborrheic dermatitis; perioral dermatitis;
             corticosteroid-induced acne or folliculitis)

          5. Use of tanning booths or excessive sun exposure, in the opinion of the investigator

          6. Active cystic acne or acne congoblata, acne fulminans, and secondary acne

          7. Two or more active nodular lesions

          8. Treatment with over-the-counter topical medications for the treatment of acne vulgaris
             including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids,
             α-hydroxy/glycolic acid on the face within 2 weeks prior to baseline

          9. Treatment with systemic corticosteroids (including intranasal and inhaled
             corticosteroids) within 4 weeks prior to baseline

         10. Treatment with systemic antibiotics or systemic anti-acne drugs or systemic
             anti-inflammatory drugs within 4 weeks prior to baseline

         11. Prescription topical retinoid use on the face within 4 weeks of baseline (e.g.,
             tretinoin, tazarotene, adapalene)

         12. Treatment with hormonal therapy or dose change to hormonal therapy within 12 weeks
             prior to baseline. Dose and frequency of use of any hormonal therapy started more than
             12 weeks prior to baseline must remain unchanged throughout the study. Hormonal
             therapies include, but are not limited to, estrogenic and progestational agents such
             as birth control pills.

         13. Use of androgen receptor blockers (such as spironolactone or flutamide)

         14. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A
             supplements greater than 10,000 units/day within 6 months of baseline

         15. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the 8 weeks
             of the first dose or during the study

         16. A positive urine drug screen for drugs of abuse, including alcohol or positive urine
             cotinine (≥300 ng/mL for cotinine) at the screening visit or at entry to the clinic
             (Note: urine cotinine required at screening visit only)

         17. Treatment with any investigational drug within 30 days or 5 half-lives (whichever is
             longer) prior to the beginning of the screening period (this includes investigational
             formulations of marketed products, inhaled and topical drugs)

         18. Hypersensitivity to B244 or its components

         19. Blood collection of greater than 500 mL within 56 days prior to screening

         20. Seropositive for human immunodeficiency virus (HIV) at screening

         21. Positive for Hepatitis B virus surface antigen (HBsAg) or positive Hepatitis C virus
             antibody (HCV Ab) at screening

         22. Any other condition and/or situation that causes the Investigator to deem a subject
             unsuitable for the study (e.g., due to expected study medication non-compliance,
             inability to medically tolerate the study procedures, or a subject's unwillingness to
             comply with study-related procedures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stephens Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stephens Associates</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2017</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose I</title>
          <description>BB244 Dose I : 10 pumps of spray applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Dose II</title>
          <description>BB244 Dose II : 10 pumps of spray applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Dose III</title>
          <description>BB244 Dose III: 10 pumps of spray applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: 10 pumps of spray applied BID twice a day to the entire face for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects were adult men or women, between the ages of 18 and 45 years.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose I</title>
          <description>B244 dose strength I
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Dose II</title>
          <description>B244 dose strength II
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Dose III</title>
          <description>B244 dose strength III
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo
Placebo: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="10.0"/>
                    <measurement group_id="B2" value="26" spread="8.2"/>
                    <measurement group_id="B3" value="29.2" spread="4.8"/>
                    <measurement group_id="B4" value="31.7" spread="10.1"/>
                    <measurement group_id="B5" value="29.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety (Number of Participants With Treatment Related Adverse Events)</title>
        <description>Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses</description>
        <time_frame>4 weeks</time_frame>
        <population>The safety analysis set included all subjects in the ITT/Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose I</title>
            <description>B244 dose I
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Dose II</title>
            <description>B244 dose II
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Dose III</title>
            <description>B244 dose III
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety (Number of Participants With Treatment Related Adverse Events)</title>
          <description>Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses</description>
          <population>The safety analysis set included all subjects in the ITT/Safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy</title>
        <description>Absolute Change from Baseline in Total Number of Lesions</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>All efficacy and safety data were analyzed using the ITT/Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Active Doses</title>
            <description>Pooled Active Doses (Doses I, II, III)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy</title>
          <description>Absolute Change from Baseline in Total Number of Lesions</description>
          <population>All efficacy and safety data were analyzed using the ITT/Safety population.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="12.09"/>
                    <measurement group_id="O2" value="-6.7" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were monitored for Adverse Events from Study Day 1 through Day 28 of the study</time_frame>
      <desc>During each visit, the Investigator questioned the subject about adverse events using an open question taking care not to influence the subject’s answers, e.g., &quot;have you noticed any change in your health?”</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose I</title>
          <description>B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Dose II</title>
          <description>B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Dose III</title>
          <description>B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
B244: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo
Placebo: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary Tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Streptococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Masha Gaber</name_or_title>
      <organization>AOBIOME</organization>
      <phone>617-475-1605</phone>
      <email>mgaber@aobiome.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

